Donald M. Jensen

<p>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy</p>

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.

Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer

Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection

Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?

The benefit of paracentesis on hospitalized adults with cirrhosis and ascites

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Sticker shock and the price of new therapies for hepatitis C: Is it worth it?

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Predictive value of <scp>ALT</scp> levels for non‐alcoholic steatohepatitis (<scp>NASH</scp>) and advanced fibrosis in non‐alcoholic fatty liver disease (<scp>NAFLD</scp>)

JUMP-C: A Randomized Trial of Mericitabine Plus Pegylated Interferon Alpha-2a/Ribavirin for 24 Weeks in Treatment-NaÏVe HCV Genotype 1/4 Patients

Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin